Harmony Biosciences
(NASDAQ) HRMY
Harmony Biosciences Financials at a Glance
Market Cap
$1.82B
Revenue (TTM)
$899.11M
Net Income (TTM)
$145.62M
EPS (TTM)
$2.48
P/E Ratio
12.64
Dividend
$0.00
Beta (Volatility)
0.85 (Low)
Dividend
$0.00
Beta (Volatility)
0.85 (Low)
Price
$30.53
Volume
22,074
Open
$31.22
Price
$30.53
Volume
22,074
Open
$31.22
Previous Close
$30.53
Daily Range
$30.31 - $31.22
52-Week Range
$25.52 - $40.87
Dividend
$0.00
Beta (Volatility)
0.85 (Low)
Price
$30.53
Volume
22,074
Open
$31.22
Previous Close
$30.53
Daily Range
$30.31 - $31.22
52-Week Range
$25.52 - $40.87
HRMY News
HRMY: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Harmony Biosciences
Industry
Pharmaceuticals
Sector
Health CareEmployees
293
CEO
Jeffrey M. Dayno, MD
Website
www.harmonybiosciences.comHeadquarters
Plymouth Meeting, PA 19462, US
HRMY Financials
Key Financial Metrics (TTM)
Gross Margin
77%
Operating Margin
21%
Net Income Margin
16%
Return on Equity
18%
Return on Capital
18%
Return on Assets
11%
Earnings Yield
7.91%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.82B
Shares Outstanding
57.89M
Volume
22.07K
Avg. Volume
899.48K
Financials (TTM)
Gross Profit
$670.11M
Operating Income
$208.47M
EBITDA
$255.05M
Operating Cash Flow
$348.20M
Capital Expenditure
$310.00K
Free Cash Flow
$347.89M
Cash & ST Invst.
$775.34M
Total Debt
$239.58M
Harmony Biosciences Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$215.39M
+16.6%
Gross Profit
$170.88M
+11.9%
Gross Margin
79.33%
N/A
Market Cap
$1.82B
N/A
Market Cap/Employee
$6.78M
N/A
Employees
268
N/A
Net Income
$32.49M
-28.7%
EBITDA
$48.89M
-27.0%
Quarterly Fundamentals
Net Cash
$434.40M
+31.8%
Accounts Receivable
$108.22M
+2.1%
Inventory
$5.28M
-17.3%
Long Term Debt
$143.34M
-9.7%
Short Term Debt
$63.17M
+238.8%
Return on Assets
11.45%
N/A
Return on Invested Capital
17.97%
N/A
Free Cash Flow
$27.76M
-18.0%
Operating Cash Flow
$27.76M
-18.3%